FDA posts press releases and other notices of recalls from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

Best Life International, Inc. Recalls Ancom Anti-Hypertensive Compound Tablets

NEWS RELEASE



Contact:  Alida Atentz  
          787-832-3287

For Immediate Release

Mayaguez, PR - February 14, 2003 -- Best Life International, Inc. is recalling all 100 tablet bottles of Ancom Anti-Hypertensive Compound Tablets, an unapproved new drug labeled to contain several prescription drug ingredients, including reserpine, diazepam, promethiazine, and hydrochlorothiazide. The sale of a product with this combination of ingredients poses possible serious health risks including sedation, depression, and potentially life-threatening abnormalities of the blood.

This recall includes all lot codes of the product remaining on the market.

Ancom Tablets were sold without prescriptions to consumers through distributors and retail stores of natural products throughout the Island of Puerto Rico. The product is labeled for anti-hypertensive use and is packaged in white plastic bottles of 100 tablets bearing blue and white lettered labeling. Each bottle is sold in an outer cardboard holding carton. Both the carton and immediate container label bear the product name as Ancom tablets, Anti-hypertensive Compound, and display the manufacture’s name as Shanghai Pharmaceutical Industry Corp., Shanghai, China. The labeling also bears Chinese markings, which appear to be dual declarations. The holding carton is white with a pink and blue vertical stripe bearing blue and white lettering. The product carton also includes a pre-printed insert labeled with an ingredient statement and directions for use.

Consumers who have used this product and are experiencing any adverse reactions should seek advice from their physician for appropriate evaluation and treatment of their hypertension.

Consumers who purchased Ancom Anti-Hypertensive Compound Tablets are urged to immediately discontinue use of the product and return it to the place of purchase for a full refund. Consumers with questions may contact the company at 787-832-3287.

This recall is being conducted in cooperation with the U.S. Food and Drug Administration.

Any adverse reactions experienced with the use of this product should be reported to:

US Food and Drug Administration San Juan District 1-800-FDA-0127

FDA’s MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

####

Additional Information

FDA/Website Management Staff
Web page created by smc 2003-FEB-19.